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An important feature of gene-directed enzyme-prodrug therapy is that prodrug activation can provide diffusible cytotoxic metabolites
capable of generating a local bystander effect in tumours. Activation of the aziridinyl dinitrobenzamide CB 1954 by E. coli
nitroreductase (NTR) provides a bystander effect assumed to be due to the potently cytotoxic 4-hydroxylamine metabolite. We
show that there are four cytotoxic extracellular metabolites of CB 1954 in cultures of NTR-expressing tumour cells (the 2- and 4-
hydroxylamines and their corresponding amines). The 4-hydroxylamine is the most cytotoxic in DNA crosslink repair defective cells,
but the 2-amino derivative (CB 10-236) is of similar potency to the 4-hydroxylamine in human tumour cell lines. Importantly, CB 10-
236 has much superior diffusion properties to the 4-hydroxylamine in multicellular layers grown from the SiHa human cervical
carcinoma cell line. These results suggest that the 2-amine, not the 4-hydroxylamine, is the major bystander metabolite when CB
1954 is activated by NTR in tumours. The corresponding dinitrobenzamide nitrogen mustard SN 23862 is reduced by NTR to form a
single extracellular metabolite (also the 2-amine), which has superior cytotoxic potency and diffusion properties to the CB 1954
metabolites. These results are consistent with the reported high bystander efficiency of SN 23862 as an NTR prodrug in multicellular
layers and tumour xenografts.
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In gene-dependent enzyme-prodrug therapy (GDEPT), gene
therapy methods are used to express a prodrug-activating enzyme
in tumours. An important aspect of this approach is its ability to
generate cytotoxic metabolites that diffuse locally to cause a
bystander effect, thereby compensating in part for spatially
inhomogeneous transgene expression. Activation of the dinitro-
benzamide aziridine prodrug CB 1954 (Figure 1) by the aerobic E.
coli nitroreductase NTR (the product of the NfsB gene) has
attracted considerable attention in this context, because it provides
an efficient bystander effect in tissue culture models (Bridgewater
et al, 1997; Green et al, 1997; Friedlos et al, 1998; McNeish et al,
1998; Nishihara et al, 1998; Westphal et al, 2000; Wilson et al,
2002) and in experimental tumours (McNeish et al, 1998; Djeha
et al, 2000; Westphal et al, 2000; Wilson et al, 2002). The
combination of CB 1954 with NTR-armed adenoviral vectors is
currently in clinical trial for cancer therapy (Chung-Faye et al,
2001; Young et al, 2002). It is widely considered that the active
cytotoxic metabolite from CB 1954 (whether reduced by NTR, DT-
diaphorase or other reductases) is the corresponding 4-hydro-
xylamine (4 in Figure 1), and that this is the species responsible for
bystander effects in NTR-GDEPT. Reduction of CB 1954 with NTR
plus NADH in cell-free systems gives an equimolar mixture of the
2- and 4-hydroxylamines (Boland et al, 1991; Anlezark et al, 1992)
(Figure 1), and the 4-hydroxylamine has been shown to be the
more cytotoxic of the two metabolites (Knox et al, 1988b; Sunters
et al, 1992; Helsby et al, 2003). There is considerable evidence that
the potent cytotoxicity of the 4-hydroxylamine is related to its
ability to form DNA crosslinks via the N-acetoxy intermediate 6
(Knox et al, 1991).
The evidence that the 4-hydroxylamine of CB 1954 is responsible
for its bystander effects rests largely on a study which tentatively
identified the 2- and 4-hydroxylamines in the extracellular
medium, following incubation of NTR-expressing 3T3 cells with
CB 1954 (Bridgewater et al, 1997). It has been reported previously
that metabolism of CB 1954 by mouse liver microsomes gives the
2- and 4-amines as the end products (Walton et al, 1989), and the
amines (predominantly the 4-amine) rather than hydroxylamines
are identified as metabolites in rodents (Jarman et al, 1976; Kestell
et al, 2000). In addition, the hydroxylamine derivatives of CB 1954
are chemically unstable (Knox et al, 1993; Helsby et al, 2003),
which makes it unclear whether they will be able to diffuse
appreciable distances in tumour tissue. These considerations have
led us to revisit the identification of the metabolite(s) that
mediates the CB 1954 bystander effect. In this study, we
characterise extracellular metabolites in CB 1954-treated
NTRþve cell cultures and investigate their extravascular transport
properties in multicellular layer (MCL) cultures. The latter are
three-dimensional cell cultures useful for quantifying the tissue-
diffusion properties of drugs and metabolites (Hicks et al, 2001,
2003; Wilson et al, 2003).
In addition, we evaluate bystander metabolites from the
corresponding nitrogen mustard analogue SN 23862 (Palmer
et al, 1992). This has been suggested as an alternative NTR
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sprodrug because of its faster kinetics of reduction by NTR
(Anlezark et al, 1995) and more efficient bystander effect in MCL
cultures and human tumour xenografts (Wilson et al, 2002).
Although the 4-NO2 group is the thermodynamically preferred site
of reduction (Palmer et al, 1995), SN 23862 is reduced by NTR at
the 2-NO2 position only (Figure 1) (Anlezark et al, 1995); this
increases the reactivity of the nitrogen mustard moiety 260-fold,
and thus provides a single-step bioactivation of the prodrug,
without any requirement for N-acetoxy formation (Helsby et al,
2003).
MATERIALS AND METHODS
Chemicals
CB 1954 (1) was supplied by Professor M Jarman (Institute for
Cancer Research, Sutton, UK), and its amino derivatives 3 and 5 by
Professor Richard Knox (Enact Pharma plc, Porton Down Science
Park, Salisbury, Wiltshire SP4 0JQ, UK). The 2-and 4-hydro-
xylamines of CB 1954 (2 and 4) (Jarman et al, 1976), SN 23862 (7)
(Palmer et al, 1992) and its 2-hydroxylamine and 2-amine
derivatives 8 and 9 (Palmer et al, 1995) were synthesised as
reported. All compounds showed purities of 498% by HPLC, with
the exception of 2, which contained up to 4% of 3 and 2% of the
2,20-azoxy dimer, and 8, which contained up to 20% of 9.
Cell lines
The V79-NTR
puro line (originally named T79-A3) is a stable NTR
transfectant and V79
puro (originally T78-1) is an NTR ve clone
transfected with the corresponding empty vector (Friedlos et al,
1997). A second NTR-expressing line, SiHa-NTR
puro, was devel-
oped by transfecting the SiHa human cervical carcinoma line with
plasmid F399, a derivative of pEFIRES-P (Hobbs et al, 1998),
containing a bicistronic cassette in which the NTR and pac genes
are co-transcribed from a single EF-1a promoter. The pool was
selected in increasing concentrations of puromycin (up to 3mM).
An isolated clonogen, SiHa-NTR
puro, had growth rates similar to
SiHa and retained CB 1954 sensitivity (440-fold relative to the
parental line in 4-h exposure IC50 assays) during growth for 4
weeks in the absence of puromycin selection. Cell lines were
passaged as monolayers in aMEM containing 5% foetal bovine
serum (FBS), with added puromycin (15mM for V79-NTR
puro,3mM
for SiHa-NTR
puro) in the case of the NTR-expressing lines, for up
to 12 weeks from frozen stocks that were confirmed to be free of
mycoplasma by PCR-ELISA (Roche Diagnostics).
Prodrug metabolism in single-cell suspensions
Cells were trypsinised from late log-phase monolayers and
resuspended in aMEM containing added ascorbate (0.25mM) with
or without 5% FBS to densities up to 5 10
6cellsml
 1. The single-
cell suspensions (10ml) were stirred magnetically and gassed
continuously with 5% CO2/air in a 371C water bath. Following
equilibration for 1h, CB 1954 and SN 23862 were added from
DMSO stock solutions to give concentrations up to 100mM (final
DMSO concentration p0.5%). At various times, samples were
centrifuged to pellet cells and the extracellular medium was freshly
supplemented with ascorbate (1mM) and stored at  801C for
subsequent HPLC analysis.
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Figure 1 Products of the metabolism of the dinitrobenzamide prodrugs CB 1954 and SN 23862 by E. coli nitroreductase.
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sHPLC, mass spectrometry and fraction collection
In experiments without FBS, samples of extracellular medium were
thawed individually, centrifuged (10000g 2min), and analysed
immediately (within 3min) by HPLC, without further processing.
For samples containing FBS, 2v methanol was added and the
samples were held at  201C to precipitate proteins before
centrifugation, concentrated to ca 170ml in a centrifugal concen-
trator (Savant Instruments, Farmingdale, NY, USA), centrifuged
again and assayed immediately. The HPLC system was an Agilent
1100 (Agilent, Waldbronn, Germany) with an Alltech Altima
3.2 150mm C8 5m column (Alltech Associates Inc., Deerfield, IL,
USA). The mobile phase for the bioassay experiments comprised
linear gradients of acetonitrile in water (4–56% acetonitrile for 2–
15min, decreasing to 4% at 17min for CB1954; 16–64%
acetonitrile for 2–6min, decreasing to 16% between 12 and
15min for SN 23862) at a flow rate of 0.5mlmin
 1. In all other
experiments, 0.45 M ammonium formate buffer (pH 6.5 for CB
1954, pH 4.5 for SN 23862) replaced the water in the mobile phase.
Detection was by diode array absorbance at 330nm for CB 1954
and 272nm for SN 23862 (bandwidth 4nm, reference wavelength
500–600nm). Phenol red in the culture medium was used as
internal standard to correct for the evaporative concentration of
samples during incubation. In some experiments, metabolites were
identified by on-line mass spectrometry using a single-stage
quadrupole mass detector (Agilent MSD model D) with negative
mode atmospheric pressure chemical ionisation, using N2 as the
nebulising and drying gas at a flow rate of 5lmin
 1 and a
nebulising pressure of 55psi. The gas temperature was 3501C, the
vaporiser temperature was 4501C, the capillary voltage was 4000V
and the corona current was 4mA. Mass spectra were also collected
using flow-injection analysis of fractions of the HPLC eluate, using
an injection cycle time of 0.8min. HPLC fractions were collected
(12-s intervals between 5 and 15min, and 30-s intervals between
0–5 and 5–20min) for bioassay and/or off-line mass spectro-
metry.
Cytotoxicity assays
The bioactivity of HPLC fractions was determined by immediately
diluting 10ml into cultures of UV4 cells in 96-well plates (seeded
at 300 cells in 100ml per well 24h previously), and then
making three-fold dilutions across the plate. The cultures were
incubated in aMEM containing 5% FBS at 371C for 96h and
cell densities determined by staining with sulphorhodamine B
(Skehan et al, 1990). The cytotoxic potencies of DMSO stock
solutions of the prodrugs and synthetic metabolites were
determined similarly, but with 4h drug exposure of Chinese
hamster fibroblasts (UV4, V79, AA8) and human tumour cells
(SiHa, WiDr), essentially as previously (Wilson et al, 1996). IC50
values were determined by logistic interpolation as the drug
concentration required to reduce cell density to 50% of that of
controls on the same plate.
Transport of potential bystander metabolites through
multicellular layers
MCL were grown by seeding 0.6 10
6 SiHa or 1 10
6 SiHa-
NTR
puro cells onto collagen-coated Millicell-CM membranes
(Millipore, Bedford, MA, USA) and grown for 4 days, submerged
in a stirred chamber of aMEM containing 10% FBS, 100IUml
 1
penicillin and 100mgml
 1 streptomycin for MCLs approximately
200mm in thickness; full details of the method for growing MCLs
are given elsewhere (Wilson et al, 2003). The MCLs were mounted
in a two-chamber diffusion apparatus (Hicks et al, 2001) with 8ml
aMEM without FBS in each compartment. For SiHa-NTR
puro
MCLs, CB 1954 or SN 23862 was added to the ‘donor’ compartment
(100mM), and the prodrug and metabolites were monitored in both
the donor and receiver compartments by storing samples at
 801C, and then directly injecting onto the HPLC within minutes
of thawing. Transport of 4 (100mM initial concentration in the
donor compartment) across SiHa
WT MCLs was measured simi-
larly.
RESULTS
Metabolism of CB 1954 by NTR-expressing cells
The overall rate of CB 1954 metabolism in cells was monitored by
measuring the extracellular concentration in stirred cell suspen-
sions, using direct HPLC analysis of the extracellular medium
(without FBS). Using NTRþve cells, disappearance of the prodrug
displayed first-order kinetics, and was much faster than with
NTR ve cells (Table 1). The rate of metabolism by SiHa-NTR
puro
cells was 2.75-fold faster than V79-NTR
puro cells, consistent with
the more intense NTR band observed in Western blots from the
former cell line (data not shown).
Consumption of CB 1954 by both NTRþve cell lines
was accompanied by formation of multiple extracellular
metabolites, as illustrated by the chromatogram in Figure 2A
(5 10
6 V79-NTR
puro cellsml
 1, 3h). In this experiment,
4ml of extracellular medium (containing 5% FBS) was
deproteinised, concentrated and analysed by HPLC. The metabo-
lites were identified by comparison of retention times, absorbance
spectra and on-line mass spectra with authentic (synthetic)
standards. The mass spectra gave prominent parent molecular
ions at the expected m/z values: 2-hydroxylamine 2 and 4-
hydroxylamine 4 ([M–H]
 ¼237.1), 2-amine 3 and 4-amine 5
([M–H]
 ¼221.1) and 2,20azoxy derivative ([M–H]
 ¼455),
which is a known product from dimerisation of 2 and the
corresponding nitroso compound (Helsby et al, 2003). Thus, the
major extracellular products from NTR reduction of CB 1954 in
V79-NTR
puro cells include the 2- and 4-amines, as well as the
primary hydroxylamine metabolites.
Bioactivity of CB 1954 metabolites
The eluate from the same chromatogram (Figure 2A) was
bioassayed by immediate dilution into cultures of UV4 cells,
which are sensitive to alkylating agents because of a defect in
nucleotide excision repair (Hoy et al, 1985). In addition to the
weak cytotoxicity of residual CB 1954, four peaks of bioactivity
were detected. The greatest activity co-eluted with the 4-hydro-
xylamine 4 as expected, but the 2-hydroxylamine (2), the 2-amine
(3) and the 4-amine (5) also showed significant cytotoxicity, while
the unidentified metabolite U1 and the 2,20-azoxy dimer were not
bioactive. Serial dilution of the HPLC fractions (Figure 2B)
confirmed that the most bioactive species was 4, but the
Table 1 Kinetics of metabolic consumption of dinitrobenzamide
prodrugs by NTR-expressing and control cells at 10
6cellsml
 1, determined
by monitoring loss with time in the extracellular medium
First-order rate constant k (h
 1)
a
Cell line CB 1954 SN 23862
V79
puro 0.001070.0004 0.002070.0001
V79-NTR
puro 0.0870.03 0.1770.003
SiHa 0.006670.0001 o0.001
SiHa-NTR
puro 0.2270.06 0.670.2
aExperiments were performed using a cell density of 5 10
6ml
 1 for the V79 lines
and SiHa, and 2.5 10
5ml
 1 for SiHa-NTR
puro. Values are means7s.e.m. for 2–3
cell suspensions, corrected to a cell density of 10
6ml
 1.
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scontribution of the other reduction products was only slightly less
(and collectively of a similar order to 4).
This somewhat surprising finding led us to compare the
cytotoxic potencies of the synthetic samples of the amine and
hydroxylamine reduction products of CB 1954, using IC50 assays
with 4h drug exposure and a subsequent growth period of 4 days
(Table 2). This confirmed that 4 is the most potent cytotoxin in the
repair-defective UV4 cell line, but unexpectedly was 11–70-fold
less potent in the four repair competent cell lines tested. The 2-
amine 3 was more toxic than the 4-amine 5, and was at least as
potent as 4 in the human tumour cell lines (SiHa and WiDr). The
4-hydroxylamine and 2-amine both showed higher potency against
the ERCC1-deficient line UV4 than its parental line AA8 (63- and
seven-fold, respectively), suggesting that both these metabolites
form DNA adducts that are substrates for nucleotide excision
repair.
Extravascular diffusion properties of the cytotoxic CB 1954
metabolites
We next compared the ability of all the four cytotoxic metabolites
to diffuse in tumour tissue by testing their transport through
MCLs. Initially, the metabolites were generated in situ in MCLs
grown from SiHa-NTR
puro (Figure 3); this cell line was used in
preference to V79-NTR
puro, since the latter does not grow
uniformly as MCLs. It was first demonstrated that SiHa-NTR
puro
gives the same spectrum of extracellular metabolites as V79-
NTR
puro (Figure 3A), and the time course of formation of these
metabolites was determined in stirred single-cell suspensions
(Figure 3B). This showed that the major extracellular metabolites
are the 2- and 4-hydroxylamines and the 2-amine, with lower
concentrations of the 4-amine.
To generate the metabolites in SiHa-NTR
puro MCLs, CB 1954 was
added to the donor compartment of the diffusion chamber. As
expected, given the CB 1954 concentration gradient through the
MCL under these conditions, the metabolites that diffused out of
the MCL were at higher concentration on the donor than the
receiver side. Notably, the 2- and 4-amines (3 and 5) accumulated
in both compartments, while the 4-hydroxylamine 4 was observed
only transiently at low concentrations in the donor, and was not
detected at all in the receiver compartment. The 2-hydroxylamine
2 was not detected in either compartment. Thus, the relative yields
of the reduced metabolites in the medium bathing MCLs is quite
different from that obtained from single-cell suspensions, and
suggests that the relatively stable amine end products have
diffusion ranges much greater than the hydroxylamines in tumour
tissue.
To further evaluate the tissue transport properties of the 4-
hydroxylamine, 4 (100mM) was added to the donor compartment
of diffusion chambers containing either SiHa MCLs or the bare
support membranes (collagen-coated porous Teflon) on which the
MCLs are grown (Figure 4). Rapid loss was observed from the
donor in both cases, in part accounted for by the formation of the
4-amine 5, but the appearance of 4 in the receiver compartment
was greatly reduced in the presence of an MCL, confirming its
inefficient extravascular diffusion.
Activation of SN 23862 by NTR-expressing cells and
extravascular transport of metabolites
SN 23862 (7), a nitrogen mustard analogue of CB 1954, was also
consumed by V79-NTR
puro and SiHa-NTR
puro cells with first-order
kinetics, with higher rate constants than for CB 1954 (Table 1); this
is consistent with the improved kcat for this substrate (Anlezark
et al, 1995). Four extracellular metabolites were observed in the
medium from V79-NTR
puro cell suspensions (Figure 5A); three of
these were identified by mass spectrometry and by comparison
with synthetic standards as the 2-amine 9 ([M–H]
 ¼319) and its
corresponding mono-ol (10,[ M – H ]
 ¼301) and di-ol (11,[ M –
H]
 ¼283) mustard hydrolysis products (see Figure 1). In this
case, the 2-amine 9 was the only cytotoxic metabolite detected by
bioassay of the HPLC eluate against UV4 cells (Figure 5A upper
trace) and, when examined over a range of dilutions, had much
greater activity than the residual SN 23862 (Figure 5B). The potent
cytotoxicity of 9 was confirmed in IC50 assays with authentic
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Figure 2 Extracellular metabolites of CB 1954 in V79-NTR
puro cell
suspensions (5 10
6ml
 1, 3h). (A) Absorbance chromatogram at 330nm
(lower) and biochromatogram (upper) determined using a 1:135 dilution
of HPLC fractions into UV4 cell cultures. U1, unknown product; *phenol
red. (B) Comparison of cytotoxicity of the bioactive extracellular products.
The abscissa is the dilution factor in the bioassay.
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scompound (Table 2), which demonstrated a similar potency to the
2-hydroxylamine 8 (not detected as an extracellular metabolite)
and a higher potency than any of the CB 1954 metabolites in all cell
lines (except AA8, in which case 9 and 4 were similar, based on a
single determination for 4).
SiHa-NTR
puro cells generated an SN 23862 extracellular meta-
bolite profile (Figure 6A) similar to V79-NTR
puro (Figure 5), with
kinetics consistent with the expected precursor–product relation-
ships (conversion of 9 to 10 and then 11). When SN 23862 was
reduced in situ in SiHa-NTR
puro MCLs, the appearance of
Table 2 Cytotoxicities of the synthetic metabolites of CB 1954 (1) and SN 23862 (7) against NTR ve cell lines
IC50 (lM) following 4h drug exposure
Cmpd SiHa WiDr V79
puro AA8 UV4 AA8/UV4
a
1 277736 485734 29507113 24807260 135728 22.175.2
(CB 1954)
2 n.d.
b n.d. n.d. 22 6.3 3.4
3 7.973.3 21735 6 772 8 78 3.770.7 7.171.0
4 45792 6 75 6.970.6 3976 0.6270.05 6375
5 163739 141734 238766 2 712 4775 1.270.1
7 4800 41000 4500 ca1000
c 761789 ca 1.3
(SN 23862)
8 2.0770.08 1.270.1 1.7470.23 2.370.1 0.04570.001 5171
9 2.571.1 2.7570.15 3.9470.19 8.871.1 0.2370.04 4074
Values are mean7s.e.m. for 2–15 (median 4) independent experiments.
aIntra-experiment IC50 ratio.
bNot determined.
cIC50 above the solubility limit in some experiments.
Time (min)
0 50 100 150 200
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(

M
)
0
2
4
6
8
10
12
14
4
5
3
2
Time (min) 
0 50 100 150 200 250 300 0 50 100 150 200 250 300
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(

M
)
0
2
4
6
8
10
Time (min) 
0.0
0.2
0.4
0.6
0.8
1.0
Efflux of CB 1954 metabolites from SiHa-NTR 
puro  MCls
CB 1954 extracellular metabolites, SiHa-NTR 
puro single cells
B
A
Retention time (min)
08 41 2 1 6
A
b
s
o
r
b
a
n
c
e
 
(
m
A
U
)
 
0
10
20
30
40
50
60
4
5
U1
3
2
1 *
A
D C
Donor  Receiver
Figure 3 Extracellular metabolites of CB 1954 in SiHa-NTR
puro single-cell suspensions (A,B) and multicellular layers (C,D). (A) HPLC chromatogram
(absorbance) of extracellular medium after incubation of cells with 100mM CB 1954 for 3h at 2.5 10
5cellsml
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puro MCLs during exposure to CB
1954 (initial concentration 100mM in the donor compartment). Symbols as in (B).
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smetabolites in the medium (Figure 6C and D) showed a pattern
similar to that in single-cell suspensions (Figure 6B). Concentra-
tions of metabolites were lower on the receiver side as expected,
but all the three diffused relatively efficiently. The initial flux
of the bioactive metabolite 9 was ca 0.5mMh
 1, which was faster
than that of the less-potent CB 1954 metabolite 3 (initial flux
ca 0.2mMh
 1).
DISCUSSION
An important feature of the NTR/CB 1954 enzyme/prodrug system
for arming gene therapy vectors is that it generates cytotoxic
product(s) capable of bystander killing of cells that do not express
NTR. It has previously been shown that incubation of NTR-
transduced cells with CB 1954 generates cytotoxic activity in
extracellular medium, suggesting that the bystander effect results
from passive diffusion of a lipophilic metabolite without any
requirement for gap junctional communication or other cell–cell
contact (Bridgewater et al, 1997). The latter study noted the
formation of two extracellular radiolabelled metabolites suggested
to be the 2- and 4-hydroxylamines. It has subsequently been
assumed that the 4-hydroxylamine is the key mediator of CB 1954
bystander effects, because of its potent cytotoxicity in low cell
density cultures. The present study challenges this view, and
demonstrates that other reduction products from CB 1954,
particularly its 2-amine 3 (CB 10-236), are likely to play important
roles in its bystander effects in tumours.
We have used a high-resolution HPLC method, with on-line
mass spectrometry, to identify five extracellular metabolites from
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abscissa is the dilution factor in the bioassay.
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sCB 1954. Bioassay of the HPLC eluate against UV4 cells showed
four of these (the 2- and 4-hydroxylamines 2 and 4, and
corresponding amines 3 and 5) to have appreciable cytotoxicity.
The amines have not previously been reported as end products of
metabolism by NTR in cells, but their formation is expected, given
the sensitivity of the hydroxylamines of CB 1954 to disproportio-
nation to the nitroso and amino derivatives (Helsby et al, 2003).
The loss of the 4-hydroxylamine (4) in culture medium, and the
formation of the corresponding 4-amine (5) is little affected by the
presence of cells (Figure 4), suggesting that spontaneous chemical
conversion is the major pathway, but a contribution from cellular
reduction of the hydroxylamines is not excluded at high cell
density in tumours.
The biological importance of metabolites other than the 4-
hydroxylamine is underscored by two observations. First, although
4 is more cytotoxic than the corresponding 2-hydroxylamine (2)
against UV4 cells, it is not the most potent metabolite against
repair-competent cells (Table 2). In particular, the 2-amine (3) has
a lower IC50 than the 4-hydroxylamine (4) against the human
tumour cell lines (SiHa and WiDr). The high cytotoxicity of the 2-
amine (relative to the 4-amine or CB 1954) against AA8 cells has
been reported previously (Kestell et al, 2000), and, in the original
study on the formation of the 4-hydroxylamine (4) from CB 1954,
it was also noted that the 2-amine is much more potent than the 4-
amine against Walker cells (Knox et al, 1988b), although no direct
comparison was made with the 4-hydroxylamine in either of these
studies. The differential toxicity of the 2-amine (3) in the NER-
defective line (ratio of AA8/UV4 IC50 values in Table 2) indicates
that it is a DNA alkylator (like the 4-hydroxylamine, (4), but the
lower ratio (7.1 vs 63) suggests that it may form monoadducts
rather than crosslinks. The cytotoxicity of the 2-amine may be due
to the electronic activation of the aziridine moiety, the nucleophilic
reactivity of which is enhanced to a greater extent by reduction of
the 2-NO2 than the 4-NO2 group of CB 1954 (Helsby et al, 2003).
We have not excluded the possibility that 3 undergoes further
bioactivation in target cells, such as by reduction of the 4-NO2
group by NTR or by another potential nitroreductase such as DT-
diaphorase. Indeed, rat DT-diaphorase is known to metabolise 3
(Knox et al, 1988a). However, if any such secondary activation
occurs, it does not result in a significant new bystander metabolite,
as no unassigned bioactive peaks are observed in the extracellular
medium.
The second observation is that the amine metabolites have
greater diffusion ranges in 3D cell cultures than the corresponding
hydroxylamines, as demonstrated by the change in metabolite
profile in extracellular medium when CB 1954 is activated by SiHa-
NTR
puro cells in MCLs vs single cells in suspension (Figure 3). In
single-cell suspensions, the hydroxylamines are prominent, but
when CB 1954 is reduced within MCLs the amines are the main
species in the medium and obviously diffuse efficiently as they
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Figure 6 Extracellular metabolites of SN 23862 in SiHa-NTR
puro single-cell suspensions (A,B) and multicellular layers (C,D). (A) HPLC chromatogram
of extracellular medium after incubation of cells with 100mM SN 23862 for 3h at 2.5 10
5cellsml
 1. U2, unknown product; *phenol red. (B) Time course
of formation of extracellular metabolites as in (A). (C,D) Appearance of metabolites in medium during incubation of SiHa-NTR
puro MCLs to SN 23862
(initial concentration 100mM in the donor compartment). Symbols as in (B).
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the MCLs. The inefficient transport of the 4-hydroxylamine (4)
relative to the corresponding amine (5) was confirmed by the
failure of 4 to penetrate SiHa MCLs, while 5 (formed from 4 during
this experiment) was able to do so (Figure 4). To the extent that
MCLs model the extravascular compartment of tumours, this
would indicate that the 4-hydroxylamine is unlikely to kill
NTR ve cells efficiently in tumours, unless they are immediately
adjacent to the NTRþve cells. The superior extravascular
transport of the amines relative to the hydroxylamines is
consistent with their slightly greater lipophilicity (lipophilicity
substituent constant p  1.23 for NH2 vs  1.34 for NHOH; (Hansch
and Leo, 1979) and considerably greater stability (Helsby et al,
2003 and this study).
When the yield, cytotoxicity and tissue-penetration properties
are considered for each CB 1954 metabolite, the 2-amine (3)
emerges as a critical extracellular metabolite and a leading
contender as the species responsible for bystander effects of CB
1954 when activated by NTR in tumours. This is likely to be the
dominant metabolite at longer diffusion distances, with the 4-
hydroxylamine (4) possibly contributing to short-range bystander
killing. The contribution of these species can be expected to
change depending on the specific geometry of the diffusion
problem, which, in turn, will reflect the microregional distribution
of the NTR vector. We would predict, for example, that bystander
effects for NTR-armed Clostridia sporogenes (Lemmon et al, 1997)
localised in necrotic regions of tumours will depend to a greater
extent on the 2-amine metabolite (3), while the 4-hydroxylamine
(4) will make a larger contribution in tumours grown as intimate
mixtures of NTRþve and  ve cell lines. The formation of two
distinct bystander metabolites might be an advantage if the
mechanisms of cell killing by 3 and 4 differ to the extent that cross-
resistance between them is incomplete.
These considerations call into question whether it would be
advantageous to activate CB 1954 only by reduction at the 4-NO2
group. Anlezark et al (2002) have recently characterised such a
reductase from Bacillus amyloliquifaciens and suggested that this
may be preferable for GDEPT applications, because it provides
only the more toxic 4-hydroxylamine metabolite. Our results
suggest that reduction of the 2-NO2 group is at least as important.
We would expect E. coli NTR to be preferable to rat DT diaphorase
(which also reduces only the 4-NO2 group of CB 1954) for GDEPT
application for this same reason, in addition to its faster kinetics of
reduction (Knox et al, 1992).
Finally, this study shows that the nitrogen mustard analogue of
CB 1954, SN 23862 (7), is reduced more rapidly than CB 1954 by
NTRþve cells (Table 1), as previously reported with purified NTR
(Anlezark et al, 1995), and forms just a single bioactive
extracellular metabolite when reduced in either V79-NTR
puro
(Figure 5) or SiHa-NTR
puro cells (Figure 6). This metabolite is
also the 2-amino reduction product (9), which has superior
potency to any of the CB 1954 metabolites, especially against the
two human cell lines tested (Table 2). The initial rate of appearance
of this metabolite from SiHa-NTR
puro in extracellular medium
(Figure 6B) is considerably faster than that of 3þ4 from CB 1954
(Figure 3B), and it shows very efficient diffusion within SiHa-
NTR
puro MCLs (Figure 6B,C). All these factors indicate that SN
23862 should provide more efficient bystander effects than CB
1954 in NTR-GDEPT; this is consistent with the reported superior
bystander killing by SN 23862 in MCLs and xenografts comprising
mixtures of NTRþve and  ve WiDr cells (Wilson et al, 2002).
Whether such metabolites might diffuse too well, and thus
contribute to systemic toxicity, needs to be evaluated critically,
but we have not seen evidence of increased toxicity to either CB
1954 or SN 23862 in mice bearing NTR-expressing tumours.
Analogues of SN 23862 that provide more potent 2-amino
metabolites, and which have improved formulation characteristics,
are currently in development in this laboratory.
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